Biotechnology News and Research

RSS

Growth of biotechnology in LA depends on social cooperation

Stronger connections among businesses, universities and, most importantly, people are necessary if the biotechnology industry is going to survive and thrive in Los Angeles, according to a new study by Professor Steven Casper at Keck Graduate Institute (KGI).

17 Sep 2009

Three senior analysts appointed by Jefferies for healthcare equity research

Jefferies today announced the expansion of its Healthcare Equity Research effort with the hiring of three senior analysts. Corey Davis, PhD has joined as a Managing Director covering Specialty Pharmaceuticals, Thomas Wei will join next month as a Managing Director covering Biotechnology, and Jon Davis Wood will join later this month as a Senior Vice President covering Life Sciences Tools. All three professionals will be based in New York.

17 Sep 2009

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

17 Sep 2009

Nuveta closes Series A seed financing round for in vitro fertilization research

Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.

17 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Bioheart's MARVEL Phase II/III clinical trial successful

Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.

17 Sep 2009

GENova to sign extensive collaboration agreement with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it is in final negotiations with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments for an extensive collaboration agreement.

17 Sep 2009

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

17 Sep 2009

Avaxia Biologics receives NIH grant to develop an antibody therapeutic for oral mucositis

Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis.

17 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Researchers study the impact of obesity on body muscles

Experts at The University of Nottingham are working on ground-breaking research to determine, for the first time, precisely what damage obesity can inflict on the muscles in our body.

16 Sep 2009

Teva announces availability of its Plan B One-Step emergency contraceptive over-the-counter

Teva Women’s Health, Inc. announced today that its Plan B® One-Step (levonorgestrel) tablet, 1.5 mg emergency contraceptive is now available at licensed U.S. retail pharmacies. Approved by the U.S. Food and Drug Administration (FDA) on July 10, Plan B® One-Step can help prevent an unintended pregnancy after unprotected sex or contraceptive failure with just one pill in one dose.

16 Sep 2009

Applied Biosystems launches MeltDoctor High-Resolution Melt Reagents for scanning DNA

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the launch of genomic analysis tools that will help researchers in studies that associate genetic variation with specific diseases. These new tools, known as the MeltDoctor™ High-Resolution Melt (HRM) Reagents, are for research use only and are part of a PCR-based workflow that enables researchers to cost-effectively scan DNA from a variety of biological sample types to detect the smallest genetic variations among samples.

16 Sep 2009

Role of society and business in advancing global efforts to fight climate change

Heads of state, United Nations agency heads and CEOs of the world’s top businesses will gather in New York on Tuesday, September 22, at the United Nations Summit on Climate Change to explore the role business and society can play in advancing global efforts to fight climate change.

16 Sep 2009

BioCision's partnership with Therapak for distributing its products in clinical market

BioCision LLC, the CoolRack company, today announced that it has entered into an agreement with Therapak Corporation for the distribution of BioCision’s products into the clinical market. The deal marks BioCision’s first distribution agreement for the clinical market and expands its access to clinical settings across the United States and Europe.

16 Sep 2009

Aptuit obtains the CEO Cancer Gold Standard accreditation

Aptuit, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

16 Sep 2009

Perceptive Informatics utilizes Optasia's KneeAnalyzer software

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has enhanced its capabilities to provide medical imaging measurements for osteoarthritis clinical trials through an alliance with Optasia Medical, Inc.

From Parexel 16 Sep 2009

GENova in advanced negotiations to acquire patents from TheraGlass

GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

16 Sep 2009

Linguistic Systems is MBC's first language translation member

Linguistic Systems, Inc. (LSI), a leading provider of language translation services, today announced that it has joined the Massachusetts Biotechnology Council (MBC) as the first language translation member in the organization.

16 Sep 2009

Six research project grants aimed at improving human health awarded

Six research project grant awards totaling $5.1 million will be made to Washington life sciences organizations and their partners, the state’s Life Sciences Discovery Fund announced today.

16 Sep 2009